News
-
-
PRESS RELEASE
Innovative Molecules Announces First Patient Dosed in Phase 2a Trial of Adibelivir (IM-250), Advancing Company into Late-Stage Clinical Development
Innovative Molecules announces first patient dosed in Phase 2a trial of Adibelivir (IM-250), advancing company into late-stage clinical development -
-
-
-
PRESS RELEASE
Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease
Alfasigma partners with Innovative Molecules for exclusive rights to Adibelivir for HSV Encephalitis treatment, a rare condition. Financial terms and patient impact explained
